Literature DB >> 8750186

Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis.

L Y Bourrguignon1, N Iida, C F Welsh, D Zhu, A Krongrad, D Pasquale.   

Abstract

CD44s (standard form of CD44) is a transmembrane glycoprotein whose external domain displays extracellular matrix adhesion properties by binding both hyaluronic acid (HA) and collagen. The cytoplasmic domain of CD44s interacts with the cytoskeleton by binding directly to ankyrin. It has been shown that post-translational modifications, such as phosphorylation (by protein kinase C), acylation (by acyl-transferase) and GTP-binding enhanced CD44's interaction with cytoskeletal proteins. Most importantly, the interaction between CD44s and the cytoskeletal protein, ankyrin, is required for the modulation of CD44s cell surface expression and its adhesion function. Recently, a number of tumor cells and tissues have been shown to express CD44 variant (CD44v) isoforms. Using RT-PCR and DNA sequence analyses, we have found that unique CD44 splice variant isoforms are expressed in both prostate and breast cancer cell lines and carcinomas. Most importantly intracellular ankyrin is preferentially accumulated underneath the patched/capped structures of CD44 variant isoform in both breast and prostate cancer cells attached to HA-coated plates. We propose that selective expression of CD44v isoforms unique for certain metastatic carcinomas and their interaction with the cytoskeleton may play a pivotal role in regulating tumor cell behavior during tumor development and metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750186     DOI: 10.1007/bf01052623

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues.

Authors:  I S Trowbridge; J Lesley; R Schulte; R Hyman; J Trotter
Journal:  Immunogenetics       Date:  1982-03       Impact factor: 2.846

2.  Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1.

Authors:  J Lesley; R Schulte; R Hyman
Journal:  Exp Cell Res       Date:  1990-04       Impact factor: 3.905

3.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.

Authors:  S Jalkanen; H Joensuu; K O Söderström; P Klemi
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

4.  Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth.

Authors:  S M Loop; T A Rozanski; R C Ostenson
Journal:  Prostate       Date:  1993       Impact factor: 4.104

5.  Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.

Authors:  K K Tanabe; L M Ellis; H Saya
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

6.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

7.  Molecular cloning and expression of Pgp-1. The mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor.

Authors:  D F Zhou; J F Ding; L J Picker; R F Bargatze; E C Butcher; D V Goeddel
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

8.  Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis.

Authors:  V B Lokeshwar; L Y Bourguignon
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

9.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

10.  Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin.

Authors:  E L Kalomiris; L Y Bourguignon
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

View more
  7 in total

1.  Intermediate Molecular Mass Hyaluronan and CD44 Receptor Interactions Enhance Neutrophil Phagocytosis and IL-8 Production via p38- and ERK1/2-MAPK Signalling Pathways.

Authors:  Cheng-Hsun Lu; Chia-Huei Lin; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Yu-Min Kuo; Ting-Syuan Lin; Chia-Li Yu; Song-Chou Hsieh
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

2.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 3.  Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression.

Authors:  Lilly Y W Bourguignon
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

4.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Authors:  Geng Zhang; Hongtao Zhang; Qiang Wang; Priti Lal; Ann M Carroll; Margarita de la Llera-Moya; Xiaowei Xu; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

Review 5.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

6.  Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Cell Biol       Date:  2000-07-10       Impact factor: 10.539

7.  PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma.

Authors:  Carlos Gustavo Hirth; Adriele Machado Dos Santos; João Batista Gadelha de Cerqueira; Francisco Vagnaldo Fechine Jamacaru; Maria do Perpétuo Socorro Saldanha da Cunha; Conceição Aparecida Dornelas
Journal:  Biomed Res Int       Date:  2018-02-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.